Top

Osteoporosis International

Published in:

01-01-2018 | Original Article

Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study

Authors: S.-M. Lin, S.-H. Yang, C.-C. Liang, H.-K. Huang

Published in: Osteoporosis International | Issue 1/2018

Abstract

Summary

A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study indicated that PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients. The risk tends to increase as the cumulative doses of PPIs increase.

Introduction

A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study investigated the association between PPI use and the risk of osteoporosis and fracture among stroke survivors.

Methods

A population-based propensity-matched retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients diagnosed with a new stroke between 2000 and 2012 were identified. After propensity score matching, 10,596 patients were enrolled, and 5298 patients were each assigned to the PPI user and non-user groups. Hazard ratios (HRs) were calculated for the risk of osteoporosis, hip fracture, and vertebral fractures according to PPI use or non-use. Sensitivity analyses were conducted to evaluate the dose effects of PPI.

Results

PPI use after stroke was associated with an increased risk of osteoporosis, hip fracture, or vertebral fracture, with an adjusted HR (aHR) of 1.28 (P < 0.001). The aHRs were also significant for each outcome: osteoporosis, 1.26 (P < 0.001); hip fracture, 1.18 (P = 0.048); vertebral fracture, 1.33 (P < 0.001). A pattern of dose effect was identified. For any event (osteoporosis/hip fracture/vertebral fracture), the aHR for PPI use of 1–90, 91–365, and > 365 cDDDs was 1.22 (P < 0.001), 1.27 (P < 0.001), and 1.66 (P < 0.001), respectively. For each outcome, the highest dose was associated with the highest risk, with aHR of 1.79 (P < 0.001), 1.41 (P = 0.039), and 1.82 (P < 0.001) for osteoporosis, hip fracture, and vertebral fracture, respectively. Age- and sex-stratified analyses revealed similar patterns.

Conclusions

PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients.

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276–1287. https://doi.org/10.1016/s0140-6736(10)62349-5 PubMedPubMedCentralCrossRef

Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767. https://doi.org/10.1016/s0140-6736(02)08657-9 PubMedCrossRef

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475. https://doi.org/10.1359/jbmr.061113 PubMedCrossRef

Carda S, Cisari C, Invernizzi M, Bevilacqua M (2009) Osteoporosis after stroke: a review of the causes and potential treatments. Cerebrovasc Dis 28(2):191–200. https://doi.org/10.1159/000226578 PubMedCrossRef

Callaly EL, Ni Chroinin D, Hannon N, Sheehan O, Marnane M, Merwick A, Kelly LA, Horgan G, Williams E, Harris D, Williams D, Moore A, Dolan E, Murphy S, Kelly PJ, Duggan J, Kyne L (2015) Falls and fractures 2 years after acute stroke: the North Dublin Population Stroke Study. Age Ageing 44(5):882–886. https://doi.org/10.1093/ageing/afv093 PubMedCrossRef

Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y (1998) Fractures after stroke. Osteoporos Int 8(1):92–95. https://doi.org/10.1007/s001980050053 PubMedCrossRef

Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124(6):519–526. https://doi.org/10.1016/j.amjmed.2011.01.007 PubMedPubMedCentralCrossRef

Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z (2016) Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis 19(9):864–868. https://doi.org/10.1111/1756-185x.12866 PubMedCrossRef

Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106(7):1209–1218; quiz 1219. https://doi.org/10.1038/ajg.2011.113 PubMedCrossRef

10.

Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8):951–959. https://doi.org/10.1592/phco.28.8.951 PubMedCrossRef

11.

Targownik LE, Goertzen AL, Luo Y, Leslie WD (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112(1):95–101. https://doi.org/10.1038/ajg.2016.481 PubMedCrossRef

12.

Igase M, Kohara K, Igase K, Yamashita S, Fujisawa M, Katagi R, Miki T (2013) Prevalence and associated clinical factors of GERD (gastro-esophageal reflux disease) in ischemic stroke patients. J Neurol Neurophysiol S8(004). https://doi.org/10.4172/2155-9562.S8-004

13.

Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E (2010) The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 10(5):281–288. https://doi.org/10.2165/11584410-000000000-00000 PubMedCrossRef

14.

Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J (2005) Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62(8):1217–1220. https://doi.org/10.1001/archneur.62.8.1217 PubMedCrossRef

15.

Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE (2011) Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 97(10):797–802. https://doi.org/10.1136/hrt.2010.217547 PubMedPubMedCentralCrossRef

16.

Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA (2011) Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 141(1):71–79. https://doi.org/10.1053/j.gastro.2011.03.049 PubMedCrossRef

17.

Niigaki M, Adachi K, Hirakawa K, Furuta K, Kinoshita Y (2013) Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan. J Gastroenterol 48(4):463–472. https://doi.org/10.1007/s00535-012-0671-3 PubMedCrossRef

18.

Lucas CE, Yu P, Vlahos A, Ledgerwood AM (1999) Lower esophageal sphincter dysfunction often precludes safe gastric feeding in stroke patients. Arch Surg 134(1):55–58. https://doi.org/10.1001/archsurg.134.1.55 PubMedCrossRef

19.

Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M (2016) Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis 25(5):1035–1040. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.01.018 PubMedCrossRef

20.

Wu T-Y, Majeed A, Kuo KN (2010) An overview of the healthcare system in Taiwan. London J Prim Care 3(2):115–119. https://doi.org/10.1080/17571472.2010.11493315 CrossRef

21.

Tsan YT, Lee CH, Wang JD, Chen PC (2012) Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30(6):623–630. https://doi.org/10.1200/jco.2011.36.0917 PubMedCrossRef

22.

Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, Yeh CB (2017) Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc 65(7):1441–1447. https://doi.org/10.1111/jgs.14813 PubMedCrossRef

23.

National Health Insurance Administration, Ministy of Health and Welfare (2016) Patients with chronic diseases (refill prescriptions). https://www.nhi.gov.tw/english/Content_List.aspx?n=8499F575B188B17E&topn=1D1ECC54F86E9050. Accessed September 20 2017

24.

Chen CH, Lin CL, Kao CH (2016) Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int 27(6):2117–2126. https://doi.org/10.1007/s00198-016-3510-1 PubMedCrossRef

25.

Lien HM, Chou SY, Liu JT (2008) Hospital ownership and performance: evidence from stroke and cardiac treatment in Taiwan. J Health Econ 27(5):1208–1223. https://doi.org/10.1016/j.jhealeco.2008.03.002 PubMedCrossRef

26.

Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH (2015) Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 201:96–101. https://doi.org/10.1016/j.ijcard.2015.07.075 PubMedCrossRef

27.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8 PubMedCrossRef

28.

Lee HC, Chang KC, Huang YC, Lan CF, Chen JJ, Wei SH (2010) Inpatient rehabilitation utilization for acute stroke under a universal health insurance system. Am J Manag Care 16(3):e67–e74PubMed

29.

Liu CYHY, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY (2006) Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey (in Chinese). J Health Manag 4(1):1–22

30.

Chang CC, Chen YT, Hsu CY, Su YW, Chiu CC, Leu HB, Huang PH, Chen JW, Lin SJ (2017) Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients. Am J Med 130(3):348–355. https://doi.org/10.1016/j.amjmed.2016.10.016 PubMedCrossRef

31.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509. https://doi.org/10.2307/2670170 CrossRef

32.

Kapral MK, Fang J, Alibhai SM, Cram P, Cheung AM, Casaubon LK, Prager M, Stamplecoski M, Rashkovan B, Austin PC (2017) Risk of fractures after stroke: results from the Ontario Stroke Registry. Neurology 88(1):57–64. https://doi.org/10.1212/wnl.0000000000003457 PubMedPubMedCentralCrossRef

33.

Batchelor F, Hill K, Mackintosh S, Said C (2010) What works in falls prevention after stroke?: a systematic review and meta-analysis. Stroke 41(8):1715–1722. https://doi.org/10.1161/strokeaha.109.570390 PubMedCrossRef

34.

Lenihan CR, Sukumaran Nair S, Vangala C, Ramanathan V, Montez-Rath ME, Winkelmayer WC (2017) Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients. Am J Kidney Dis 69(5):595–601. https://doi.org/10.1053/j.ajkd.2016.09.019 PubMedCrossRef

35.

Goss SL, Lemons KA, Kerstetter JE, Bogner RH (2007) Determination of calcium salt solubility with changes in pH and PCO₂, simulating varying gastrointestinal environments. J Pharm Pharmacol 59(11):1485–1492. https://doi.org/10.1211/jpp.59.11.0004 PubMedCrossRef

36.

O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778–781. https://doi.org/10.1016/j.amjmed.2005.02.007 PubMedCrossRef

37.

Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280(20):5052–5064. https://doi.org/10.1111/febs.12478 PubMedCrossRef

38.

Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435–2442. https://doi.org/10.1001/jama.2013.280490 PubMedCrossRef

39.

Green RH, Allen L, Bjørke-Monsen A-L, Brito A, Jean-Louis Guéant W, Miller JM, Molloy A, Nexo E, Stabler S, Toh B-H, Magne Ueland P, Yajnik C (2017) Vitamin B12 deficiency. Nat Rev Dis Primers 3:17041. https://doi.org/10.1038/nrdp.2017.41 CrossRef

40.

Herrmann M, Widmann T, Herrmann W (2005) Homocysteine—a newly recognised risk factor for osteoporosis. Clin Chem Lab Med 43(10):1111–1117. https://doi.org/10.1515/cclm.2005.194 PubMed

41.

Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B (2012) Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 51(3):376–382. https://doi.org/10.1016/j.bone.2012.05.024 PubMedCrossRef

42.

Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29(11):2489–2497. https://doi.org/10.1002/jbmr.2279 PubMedCrossRef

43.

Stabler SP (2013) Vitamin B12 deficiency. N Engl J Med 368(2):149–160. https://doi.org/10.1056/NEJMcp1113996 PubMedCrossRef

44.

Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340. https://doi.org/10.1136/bmj.b5087

45.

Wang WJ, Chao CT, Huang YC, Wang CY, Chang CH, Huang TM, Lai CF, Huang HY, Shiao CC, Chu TS, Chen YM, Wu VC, Ko WJ, Wu KD (2014) The impact of acute kidney injury with temporary dialysis on the risk of fracture. J Bone Miner Res 29(3):676–684. https://doi.org/10.1002/jbmr.2061 PubMedCrossRef

Title: Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study
Authors: S.-M. Lin
S.-H. Yang
C.-C. Liang
H.-K. Huang
Publication date: 01-01-2018
Publisher: Springer London
Published in: Osteoporosis International / Issue 1/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4262-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

Professor Judith Elizabeth Adams: Leading skeletal radiologist and expert in adult and paediatric bone densitometry

Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture—limitations and scope for fracture liaison services in prevention of hip fracture

Kyphosis and incident falls among community-dwelling older adults

Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors

Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome